CAR T cell therapy is an extraordinary advancement in the treatment of relapsed and refractory aggressive lymphomas. However, many patients still experience lymphoma relapse after CAR T cell treatment, in many cases due to the loss of the CD19 protein target. We are engineering novel CAR T cell designs to target CD19 and CD47, a potentially indispensable tumor antigen that may be required for tumor progression and immune evasion. Given that CD47 is overexpressed in many tumor types, using CAR T cells to target CD47 has therapeutic potential in lymphoma and many other cancers. We hope to apply successful designs in our syngeneic mouse model to xenograft models and later to phase I clinical trials.
- Chief Hematology Oncology Fellow, Memorial Sloan Kettering Cancer Center, 2021-2022
- Mortimer J. Lacher Fellowship Recipient at Memorial Sloan Kettering Cancer Center, 2021-2022
- Alpha Omega Alpha Honor Medical Society, 2017
- Hematology and Oncology Fellowship, Memorial Sloan Kettering Cancer Center
- Internal Medicine Residency, Brigham and Women’s Hospital, 2020
- MD, University of Massachusetts Medical School, 2017
- BA in Molecular and Cellular Biology, Harvard University, 2011